29 Biotechnology Stocks to Sell Now

29 Biotechnology Stocks to Sell Now

This week, the overall grades of 29 Biotechnology stocks are lower, according to the Portfolio Grader database. Each of these rates a “D” (“sell”) or “F” overall (“strong sell”).

Alexion Pharmaceuticals, Inc. (ALXN) slips from a C to a D this week. Alexion Pharmaceuticals, Inc. engages in the innovation, development, and commercialization of life-transforming therapeutic products for treating patients with severe and ultra-rare disorders in the United States, Europe, Latin America, Japan, and the Asia Pacific. The company also gets F’s in operating margin growth. For more information, get Portfolio Grader’s complete analysis of ALXN stock.

Blueprint Medicines Corp. (BPMC) earns a D this week, moving down from last week’s grade of C. The company also gets F’s in return on equity. For more information, get Portfolio Grader’s complete analysis of BPMC stock.

Heron Therapeutics Inc’s (HRTX) rating weakens this week, dropping to a D versus last week’s C. The company also gets F’s in earnings revisions, return on equity, and free cash flow. For more information, get Portfolio Grader’s complete analysis of HRTX stock.

Coherus BioSciences, Inc. (CHRS) declines this week from a C to a D. Coherus BioSciences, Inc. focuses on developing and commercializing biosimilar products worldwide. The company also gets F’s in earnings surprise and free cash flow. For more information, get Portfolio Grader’s complete analysis of CHRS stock.

Dynavax Technologies Corporation (DVAX) is having a tough week. The company’s rating falls from a C to a D. Dynavax Technologies Corporation discovers and develops novel products to prevent and treat infectious diseases, asthma and inflammatory and autoimmune diseases. The company also gets F’s in earnings revisions, earnings surprise, return on equity, and free cash flow. For more information, get Portfolio Grader’s complete analysis of DVAX stock.

Insys Therapeutics, Inc. (INSY) experiences a ratings drop this week, going from last week’s D to a F. Insys Therapeutics, Inc. develops pharmaceutical products that target the unmet needs of cancer patients, with a focus on cancer-supportive care. The company also gets F’s in sales growth, earnings growth, and earnings revisions. For more information, get Portfolio Grader’s complete analysis of INSY stock.

Epizyme, Inc. (EPZM) gets weaker ratings this week as last week’s C drops to a D. The company also gets F’s in sales growth and return on equity. For more information, get Portfolio Grader’s complete analysis of EPZM stock.

Slipping from a C to a D rating, Adaptimmune Therapeutics PLC Sponsored ADR (ADAP) takes a hit this week. The company also gets F’s in earnings revisions and return on equity. For more information, get Portfolio Grader’s complete analysis of ADAP stock.

This is a rough week for uniQure N.V. (QURE). The company’s rating falls to F from the previous week’s D. The company also gets F’s in earnings revisions, return on equity, and free cash flow. For more information, get Portfolio Grader’s complete analysis of QURE stock.

This week, T2 Biosystems, Inc.’s (TTOO) rating worsens to a F from the company’s D rating a week ago. The company also gets F’s in return on equity and free cash flow. For more information, get Portfolio Grader’s complete analysis of TTOO stock.

This week, Invitae Corp. (NVTA) drops from a C to a D rating. The company also gets F’s in return on equity and free cash flow. For more information, get Portfolio Grader’s complete analysis of NVTA stock.

Zafgen, Inc. (ZFGN) earns a D this week, moving down from last week’s grade of C. The company also gets F’s in return on equity and free cash flow. For more information, get Portfolio Grader’s complete analysis of ZFGN stock.

OvaScience, Inc. (OVAS) experiences a ratings drop this week, going from last week’s D to a F. The company also gets F’s in return on equity and free cash flow. For more information, get Portfolio Grader’s complete analysis of OVAS stock.

Amicus Therapeutics, Inc. (FOLD) declines this week from a C to a D. Amicus Therapeutics, Inc. is a biopharmaceutical company which is focused on the discovery, development and commercialization of orally-administered, small molecule drugs known as pharmacological chaperones. The company also gets F’s in return on equity and free cash flow. For more information, get Portfolio Grader’s complete analysis of FOLD stock.

TRACON Pharmaceuticals, Inc. (TCON) slips from a C to a D this week. The company also gets F’s in return on equity and free cash flow. For more information, get Portfolio Grader’s complete analysis of TCON stock.

Slipping from a C to a D rating, Cara Therapeutics Inc (CARA) takes a hit this week. The company also gets F’s in sales growth, return on equity, and free cash flow. For more information, get Portfolio Grader’s complete analysis of CARA stock.

This week, Trovagene, Inc.’s (TROV) rating worsens to a D from the company’s C rating a week ago. Trovagene, Inc. is developing a non-invasive testing technology using transrenal nucleic acid (TrNA) markers for infectious diseases, prenatal testing, early detection of cancer, and monitoring of organ and cell transplantation. The company also gets F’s in earnings surprise, return on equity, and free cash flow. For more information, get Portfolio Grader’s complete analysis of TROV stock.

Progenics Pharmaceuticals, Inc.’s (PGNX) rating weakens this week, dropping to a D versus last week’s C. Progenics Pharmaceuticals, Inc. develops and distributes therapeutic products to treat the unmet medical needs of patients with debilitating conditions and life-threatening diseases. The company also gets F’s in operating margin growth, earnings revisions, earnings surprise, and return on equity. For more information, get Portfolio Grader’s complete analysis of PGNX stock.

Vical Incorporated (VICL) gets weaker ratings this week as last week’s D drops to a F. Vical Incorporated researches and develops biopharmaceutical products based on its patented DNA delivery technologies for the prevention and treatment of serious or life-threatening diseases. The company also gets F’s in return on equity and free cash flow. For more information, get Portfolio Grader’s complete analysis of VICL stock.

This is a rough week for Strongbridge Biopharma plc (SBBP). The company’s rating falls to F from the previous week’s D. The company also gets F’s in earnings revisions and return on equity. For more information, get Portfolio Grader’s complete analysis of SBBP stock.

Genocea Biosciences, Inc. (GNCA) is having a tough week. The company’s rating falls from a C to a D. The company also gets F’s in return on equity and free cash flow. For more information, get Portfolio Grader’s complete analysis of GNCA stock.

This week, Kindred Biosciences, Inc. (KIN) drops from a D to a F rating. The company also gets F’s in return on equity and free cash flow. For more information, get Portfolio Grader’s complete analysis of KIN stock.

ImmunoGen, Inc. (IMGN) declines this week from a D to a F. ImmunoGen, Inc. develops pharmaceuticals, primarily for the treatment of cancer. The company also gets F’s in earnings surprise and free cash flow. For more information, get Portfolio Grader’s complete analysis of IMGN stock.

This is a rough week for CytRx Corporation (CYTR). The company’s rating falls to D from the previous week’s C. CytRx Corporation is a biopharmaceutical research and development company that specializes in oncology. The company also gets F’s in return on equity and free cash flow. For more information, get Portfolio Grader’s complete analysis of CYTR stock.

Tonix Pharmaceuticals Holding Corp. (TNXP) is having a tough week. The company’s rating falls from a D to a F. The company also gets F’s in earnings surprise, return on equity, and free cash flow. For more information, get Portfolio Grader’s complete analysis of TNXP stock.

Conatus Pharmaceuticals Inc.’s (CNAT) rating weakens this week, dropping to a F versus last week’s D. The company also gets F’s in return on equity and free cash flow. For more information, get Portfolio Grader’s complete analysis of CNAT stock.

Slipping from a D to a F rating, Infinity Pharmaceuticals, Inc. (INFI) takes a hit this week. Infinity Pharmaceuticals, Inc. researches and develops cancer drugs. The company also gets F’s in earnings revisions, return on equity, and free cash flow. For more information, get Portfolio Grader’s complete analysis of INFI stock.

Galectin Therapeutics Inc. (GALT) gets weaker ratings this week as last week’s D drops to a F. Galectin Therapeutics Inc. is a drug development company. The company also gets F’s in earnings surprise, return on equity, and free cash flow. For more information, get Portfolio Grader’s complete analysis of GALT stock.

Neothetics, Inc. (NEOT) experiences a ratings drop this week, going from last week’s C to a D. The company also gets F’s in earnings revisions, return on equity, and free cash flow. For more information, get Portfolio Grader’s complete analysis of NEOT stock.

Louis Navellier’s proprietary Portfolio Grader stock ranking system assesses roughly 5,000 companies every week based on a number of fundamental and quantitative measures. Stocks are given a letter grade based on their results — with A being “strong buy,” and F being “strong sell.” Explore the tool here.


Article printed from InvestorPlace Media, https://investorplace.com/2016/06/29-biotechnology-stocks-to-sell-now/.

©2019 InvestorPlace Media, LLC